Alvotech’s leadership team is dedicated to fostering a dynamic change-driven culture committed to meeting the needs of our customers. Our organizational structure is lean and flexible, driving quick and effective decision making and thus enabling the company to bring new biosimilar medicines quickly and safely to market.
Robert Wessman is the founder and chairman of Alvotech as well as the CEO for global generic pharmaceuticals company Alvogen. The experienced leadership team is lead by Mark Levick.
CEO of Alvotech
Chief Scientific Officer
SVP late stage development
SVP early stage development
Chief financial officer
Robert Wessman founded Alvotech in 2013 with the mission to set a new standard in biosimilars. Wessman’s initial strategy was to invest in the development and manufacture of a portfolio of biosimilar monoclonal antibodies and to build a state-of-the-art manufacturing facility in Reykjavik Iceland.